131 related articles for article (PubMed ID: 20609666)
1. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies.
Fonseca VA; Zinman B; Nauck MA; Goldfine AB; Plutzky J
Am J Med; 2010 Jul; 123(7):S2-S10. PubMed ID: 20609666
[TBL] [Abstract][Full Text] [Related]
2. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
Nauck MA
Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
[TBL] [Abstract][Full Text] [Related]
3. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
4. Incretin based therapies for type 2 diabetes mellitus.
Ghosh S; Collier A; Elhadd T; Malik I
J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
[TBL] [Abstract][Full Text] [Related]
5. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
7. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
8. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
9. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
10. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
11. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
Triplitt C; Wright A; Chiquette E
Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
13. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
Zarowitz BJ; Conner C
Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
[TBL] [Abstract][Full Text] [Related]
14. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
Kendall DM; Cuddihy RM; Bergenstal RM
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S329-39. PubMed ID: 19580952
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
[TBL] [Abstract][Full Text] [Related]
17. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
Barnett AH
Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Gilbert MP; Pratley RE
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S309-18. PubMed ID: 19580950
[TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapies: mimetics versus protease inhibitors.
Brubaker PL
Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
